First Objective Definition of Hyperacute T-waves as a ST-segment Elevation Myocardial Infarction Equivalent ECG Finding
Overview
This abstract introduces the first objective definition of hyperacute T-waves — an early and often missed ECG sign of a severe heart attack. By accurately detecting blocked arteries even before classic signs appear, the new formula helps doctors identify high-risk patients sooner and deliver life-saving treatment faster.
Key findings
- First objective, quantifiable definition of hyperacute T-waves.
- 98% specificity for occlusion MI (37% sensitivity).
- Detects blocked arteries before classic STEMI signs appear.
Published in: Journal of the American College of Cardiology (JACC) – presented at the annual ACC’25 conference
Published Date: April 1, 2025
Background
The American College of Cardiology recommends identifying hyperacute T waves (HATW) as a STEMI equivalent indicating the need for immediate invasive reperfusion strategy. Although HATW have been qualitatively described, they have no objective or quantifiable definition.
Methods
We developed a HATW rule to detect acute coronary occlusion in the absence of STEMI criteria by exploring a database of 12-lead ECGs of acute coronary syndrome patients with known angiographic outcomes. The rule applies to narrow QRS complex rhythms and requires 2 contiguous leads with both: 1) increased ratio of T-wave area to QRS amplitude (using lead-specific ratio thresholds), and 2) increased T-wave symmetry defined as T-wave peak at ≤ 67% of the J-T interval.
Results
1,333 ECGs from 605 patients (130 ECGs meeting formal STEMI criteria) were evaluated. The HATW formula demonstrated 37% sensitivity 98% specificity for acute coronary occlusion myocardial infarction among all patients, and 23% sensitivity and 98% specificity in patients without formal STEMI criteria.
Conclusion
This is the first quantitative analysis of HATW demonstrating its potential as a highly specific STEMI equivalent ECG finding of acute coronary occlusion. Further prospective validation of its performance is warranted.
Share this article
About PMcardio
PMcardio is the market leader in AI-powered diagnostics, addressing the world’s leading cause of death – cardiovascular diseases. The innovative clinical assistant empowers healthcare professionals to detect up to 40 cardiovascular diseases. In the form of a smartphone application, the certified Class IIb medical device interprets any 12-lead ECG image in under 5 seconds to provide accurate diagnoses and individualized treatment recommendations tailored to each patient.
About Powerful Medical
Powerful Medical leads one of the most important shifts in modern medicine by augmenting human-made clinical decisions with artificial intelligence. Our primary focus is on cardiovascular diseases, the world’s leading cause of death.
Established in 2017, Powerful Medical has embarked on a mission to revolutionize the diagnosis and treatment of cardiovascular diseases. We are a medical company backed by 28 world-class cardiologists and led by our expert Scientific Board with decades of experience in daily patient care, clinical research, and medical devices. The results of our research are implemented, developed, certified, and brought to market by our 50+ strong interdisciplinary team of physicians, data scientists, AI experts, software engineers, regulatory specialists, and commercial teams.
